Home
Conditions
Carcinoma, Hepatocellular

Clinical trial condition

Carcinoma, Hepatocellular

Explore clinical trials studying Carcinoma, Hepatocellular. Study availability and eligibility vary by location and protocol.

2,104 public trials 536 recruiting studies

Refine in advanced search Browse all conditions

Carcinoma, Hepatocellular trial results

Completed

A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma

NCT03418922

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +8 more
Locations: Eisai Trial Site 1 Kashiwa, Chiba, Japan

Eisai Trial Site 6 Iizuka, Fukuoka, Japan

Eisai Trial Site 3 Kawasaki, Kanagawa, Japan

Eisai Trial Site 4 Sayama, Osaka, Japan

View Trial Details

Completed

RFA Versus SBRT for Recurrent Small HCC

NCT04047173

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
Locations: Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China

View Trial Details

Completed

TACE Combined With Tyrosine Kinase Inhibitors and Tislelizumab in Unresectable Hepatocellular Carcinoma

NCT06232759

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
Locations: Jian-Hong Zhong Nanning, Guangxi, China

View Trial Details

Completed

Transarterial Chemoembolization Versus Proton Beam Radiotherapy for the Treatment of Hepatocellular Carcinoma

NCT00857805

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +8 more
Locations: Loma Linda University Medical Center Loma Linda, California, United States

View Trial Details

Completed

Comparison of Gd-EOB-DTPA-enhanced MRI and Contrast-enhanced Ultrasound for Measuring Tumor Size of Solitary Hepatocellular Carcinoma ≤ 5cm:A Retrospective Study

NCT06437457

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
Locations: Anhui Provincial Hospital Hefei, Anhui, China

View Trial Details

Completed

Lenvatinib vs Bevacizumab Plus ICIs and HAIC in Unresectable HCC

NCT06435013

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +10 more
Locations: Cancer Center Sun Yat-sen University Guangzhou, Guangdong, China

View Trial Details

Completed

A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC)

NCT04172571

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
Locations: Chinese PLA General Hospital Beijing, Beijing Municipality, China

View Trial Details

Completed

Post-marketing Surveillance on the Safety of CabometyxTM in Korean Patients

NCT03776123

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +21 more
Locations: Korea University Ansan Hospital Ansan, South Korea

Hallym University Sacred Heart Hospital Anyang, South Korea

DONG-A University Hospital (Site A) Busan, South Korea

DONG-A University Hospital (Site B) Busan, South Korea

View all 47 locations

View Trial Details

Completed

Postoperative TACE(Transhepatic Arterial Chemotherapy And Embolization) for Patients With Hepatocellular Carcinoma

NCT02109146

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +10 more
Locations: The Second Affiliated Hospital, Zhejiang University School of Medicine Hangzhou, Zhejiang, China

View Trial Details

Completed

cTACE Plus Sintilimab for Unresectable Intermediate-stage HCC With Beyond Up-to-seven Criteria

NCT04842565

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
Locations: Zhongshan Hospital Shanghai, Shanghai Municipality, China

View Trial Details

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular trial results

Related conditions